The beta3 subunit of the Na+,K+-ATPase mediates variable nociceptive sensitivity in the formalin test - PubMed (original) (raw)

. 2009 Aug;144(3):294-302.

doi: 10.1016/j.pain.2009.04.028. Epub 2009 May 22.

Gary Mo, Shad B Smith, Susana G Sotocinal, Jennifer Ritchie, Jean-Sebastien Austin, Kara Melmed, Ara Schorscher-Petcu, Audrey C Laferriere, Tae Hoon Lee, Dmitry Romanovsky, Guochun Liao, Mark A Behlke, David J Clark, Gary Peltz, Philippe Séguéla, Maxim Dobretsov, Jeffrey S Mogil

Affiliations

The beta3 subunit of the Na+,K+-ATPase mediates variable nociceptive sensitivity in the formalin test

Michael L LaCroix-Fralish et al. Pain. 2009 Aug.

Abstract

It is widely appreciated that there is significant inter-individual variability in pain sensitivity, yet only a handful of contributing genetic variants have been identified. Computational genetic mapping and quantitative trait locus analysis suggested that variation within the gene coding for the beta3 subunit of the Na+,K+-ATPase pump (Atp1b3) contributes to inter-strain differences in the early phase formalin pain behavior. Significant strain differences in Atp1b3 gene expression, beta3 protein expression, and biophysical properties of the Na+,K+ pump in dorsal root ganglia neurons from resistant (A/J) and sensitive (C57BL/6J) mouse strains supported the genetic prediction. Furthermore, in vivo siRNA knockdown of the beta3 subunit produced strain-specific changes in the early phase pain response, completely rescuing the strain difference. These findings indicate that the beta3 subunit of the Na+,K+-ATPase is a novel determinant of nociceptive sensitivity and further supports the notion that pain variability genes can have very selective effects on individual pain modalities.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Haplotype mapping implicates Atp1b3 as a candidate gene underlying variable sensitivity to formalin pain. A, Sensitivity of 16 inbred mouse strains in the early phase of the formalin test (5%, 20 μl). Bars represent mean ± SEM percentage of samples featuring licking/biting behavior from 0−5 min post-injection (_n_=10−38/strain). B, Standardized scores (_z_-scores) of data in panel a, arranged from least sensitive (left) to most sensitive (right). C, Top 10 genome-wide correlations (arranged by _p_-value) between 5,694 SNP haplotype blocks and formalin test _z_-scores. Colored blocks represent the haplotype of the 16 strains, in the left-to-right order shown in graph B (most common haplotype in red, 2nd most common in blue, 3rd most common in green, least common in yellow). The effect score represents the proportion of the observed inter-strain phenotypic difference that could be explained by genetic variation within that haplotype block.

Figure 2

Figure 2

Expression of β subunits in dorsal root ganglion tissue. qPCR analysis of A, Atp1b1, B, Atp1b2, and C, Atp1b3 mRNA expression in lumbar DRG tissue. Bars represent the mean ± SEM ratios for _n_=3 technical replicates performed on pooled DRG tissue from _n_=5−6 mice/strain. D, Representative photomicrographs of DRG sections from A/J (left) and C57BL/6J (middle) mice stained with an antibody against β3 protein. Scale bar = 30 μm. E, Quantification of β3-like immunoreactivity in DRG neurons from A/J and C57BL/6J mice. Bars represent the mean ± SEM pixel intensity; numbers represent the number of individual neuronal soma in DRG sections from _n_=4−5 mice/strain. *p<0.05 by Student's _t_-test.

Figure 3

Figure 3

DRG neurons from A/J mice have greater Na+,K+ pump currents and are ouabain insensitive compared to C57BL/6J mice. A, Measurement of the resting membrane potential and B, the stimulus threshold required to elicit an action potential in dissociated DRG neurons from A/J and C57BL/6J mice (mean ± SEM ; _n_=14−34 neurons/strain). **p<0.01 by Student's _t_-test. C, Representative traces of the Na+,K+ pump current, defined as the ouabain (1 mM)-sensitive fraction of the holding current, in dissociated DRG neurons from A/J and C57BL/6J mice. D, Quantification of Na+,K+ pump current density in A/J and C57BL/6J DRG neurons (mean ± SEM ; _n_=15−16 neurons/strain). ***p<0.001 by Student's _t_-test. Measurement of the ability of neurons to maintain repetitive firing using a 10Hz stimulation train over 300 s. The maximal action potential amplitude of A/J and C57BL/6J DRG neurons was recorded at in the presence of no drug (E) and 10 μM ouabain (F,G). There was a significant difference between strains (_F_1,400 = 149.1, p<0.001) in panel E and between C57BL/6J drug treatment groups (_F_1,400 = 56.38, p<0.001) in panel G as determined by ANOVA.

Figure 4

Figure 4

Rescue of the strain difference in early phase formalin pain behavior by intrathecal siRNA against Atp1b3. A, Wide field and B, confocal microscopy of 20-μm sections of lumbar DRG tissue from mice treated with three daily i.t injections of i-Fect + 0.5 μg/day of Cy3-labeled scrambled siRNA (red). Nuclei were counterstained with DAPI (blue). Scale bars = 100 μm (wide field) and 20 μμm (confocal).C, qPCR analysis of Atp1b3 mRNA expression in lumbar DRG tissue from C57BL/6J and A/J mice treated with i-Fect transfection reagent alone (control) or i-Fect plus one of two siRNAs targeting Atp1b3 (siRNA-1 and siRNA-2). Bars represent the percent of Atp1b3 mRNA expression as compared to the respective control groups ± SEM on pooled DRG tissue from _n_=6 mice/strain. *p<0.05 by Bonferroni post hoc test compared to same-strain control group. D, Early phase (0−5 min) and E, late phase (5−60 min) formalin-induced licking/biting in A/J and C57BL/6J mice treated with i-Fect transfection reagent alone (i-Fect), i-Fect plus a scrambled siRNA (scrm siRNA), or i-Fect plus one of two unique siRNAs targeting Atp1b3 (siRNA-1 and siRNA-2). Bars represent mean ± SEM total time spent licking (in panel D) or the percentage of sampled intervals showing licking behavior (in panel E) (_n_=8−13 mice/strain/treatment). *p<0.05 by Bonferroni post hoc test compared to same-strain saline group. F, Quantification of Na+,K+ pump current density in DRG neurons from A/J mice previous treated with i-Fect plus a scrambled siRNA (scrm siRNA) or i-Fect plus siRNA-2 for three days prior to measurement (mean ± SEM ; _n_=7−8 neurons/group). **p<0.01 by Student's _t_-test.

Similar articles

Cited by

References

    1. Abbott FV, Ocvirk R, Najafee R, Franklin KBJ. Improving the efficiency of the formalin test. Pain. 1999;83:561–569. - PubMed
    1. Arystarkhova E, Sweadner KJ. Tissue-specific expression of the Na,K-ATPase beta3 subunit. The presence of beta3 in lung and liver addresses the problem of the missing subunit. J Biol Chem. 1997;272:22405–22408. - PubMed
    1. Barr GA, Gao P, Wang S, Cheng J, Qin J, Sibille EL, Pavlidis P. Microarray analysis of gene expression following the formalin test in the infant rat. Pain. 2005;117:6–18. - PubMed
    1. Barwe SP, Anilkumar G, Moon SY, Zheng Y, Whitelegge JP, Rajasekaran SA, Rajasekaran AK. Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility. Mol Biol Cell. 2005;16:1082–1094. - PMC - PubMed
    1. Belfer I, Wu T, Kingman A, Krishnaraju RK, Goldman D, Max MB. Candidate gene studies of human pain mechanisms: a method for optimizing choice of polymorphisms and sample size. Anesthesiology. 2004;100:1562–1572. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources